Jazz Pharmaceuticals has made its targeted cancer therapeutic antibody, Ziihera, commercially available.
This follows the medicine's FDA approval for use in patients with HER-2 positive biliary tract cancer (BTC) late last year.
The cancer-fighting solution was developed using ProBioGen's GlymaxX, a technology designed to "boost the ADCC-mediated cell killing activity of a cancer antibody through glyco-engineering technology."
It works by influencing the fucosal content of the antibody, allowing it to more effectively attach to cancer cells.
This then allows for the optimised antibody-mediated cell killing activity of the ADCC product.
"The market availability of a bispecific antibody developed with the GlymaxX technology is a key milestone for us," noted Dr Gabriele Schneider, Chief Business Officer at ProBioGen.
"It's rewarding to see our technology play a role in therapies that can make a real difference for patients."
"We contributed to Ziihera's journy by providing our cell line, media and proprietary technology — which ultimately led to this treatment making it to market."
"Through the commercialisation of Ziihera, patients will have access to a promising treatment option for BTC," added CEO and founder of the Cholangiocarcinoma Foundation, Stacie Lindsey.
"This will allow them to spend more time with their loved ones and experience an improvement in their quality of life — which I believe is invaluable for the entire BTC community."